Galderma receives Positive Opinion through European Decentralised Procedure for Approval of EPIDUO® 0.3% / 2.5% gel for Acne Patient
September 27, 2016
Lausanne, 27 July 2016 - Galderma, Nestlé Skin Health’s medical solutions business, announced that it has received a Positive Opinion from 16 concerned European regulatory agencies for the market approval of EPIDUO 0.3% / 2.5% gel (adapalene/ benzoyl peroxide), for the cutaneous treatment of acne vulgaris, when comedones, numerous papules and pustules are present.